Alzheimer’s Disease Therapeutics And Diagnostics Market Set To Grow To $16bn By 2021

10 August 2018
Pharma

Visiongain has launched a new pharma report Alzheimer’s Disease Therapeutics and Diagnostics Market 2017-2027: Leading Drugs, Pipeline Drugs, Biomarkers, Leading Companies

Alzheimer’s Disease is reported to be the most common form of dementia in developed countries, with a prevalence of about 1% at the age of 65 and over 25% in people older than 85 years of age. Currently, advances in diagnostic technologies remain moderate and the Alzheimer’s Disease biomarker market is still in its infancy. It is expected that several diagnostic tools in the future will offer an accurate assessment of whether an individual has Alzheimer’s Disease, rather than one definitive diagnostic tool.

The lead analyst of the report commented ““The Alzheimer’s disease therapeutics market has been stagnant over the last few years, with many drugs failing late stage clinical trials. The overall AD market has experienced a slow growth in revenues due to the patent expiries of key drugs in major markets. There is a more positive outlook in the diagnostics market with advances in blood-based biomarkers, they are making a huge impact on clinical research of Alzheimer’s drug candidates. The Alzheimer’s Disease market will experience steady growth driven by the rising prevalence of AD and the entry of disease-modifying therapies (DMTs), including the passive immunotherapies, solanezumab, gantenerumab, and BACE inhibitors, verubecestat, which will have significant uptake in major markets”

Leading companies featured in the report include Pfizer, Eisai, Actavis, Lundbeck, Daiichi Sankyo, Novartis, TauRx, vTv Therapeutics, Eli Lilly, Amarantus Biosciences Holdings, Piramal Enterprises, GE Healthcare, Navidea, DiaGenic.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Pharmaceutical Spray Drying Market Report 2021-2031

The rising prevalence of oncological disorders, lung infections, rising demand for customised drugs coupled with new orphan diseases discoveries, are few of the major reasons responsible for development of pharmaceutical spray drying market.

25 October 2021

Read

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

Read

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

Read

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever